Saturday, 28 November, 2020

Germany may start COVID-19 vaccine program in Dec - health minister

Gustavo Carr | 23 November, 2020, 03:37

"The robust antibody and T-cell responses seen in older people in our study are encouraging", said Maheshi Ramasamy, a consultant and co-lead investigator at the Oxford Vaccine Group.

Late-stage, or Phase III, trials are ongoing to confirm the findings, researchers said, and to test whether the vaccine protects against infection with SARS-CoV-2 in a broad range of people, including people with underlying health conditions.

Indian may consider giving emergency authorisation to Pune-based Serum Institute to make its COVID-19 vaccine available for immunisation in India if the country of origin of the vaccine - United Kingdom - approves such a request made by its global license holder AstraZeneca for marketing approval of the Oxford University vaccine developed in the UK.

In a statement, the ministry said its legal and technical departments were analyzing the documents presented by the five entities and determining the best way to go about purchasing vaccines at "the opportune moment". An indigenously developed vaccine by Zydus Cadila has completed phase-two clinical trial in the country.

It is pertinent to mention here that Planning and Development Minister Asad Umar announced on September 22 the launch of phase III human clinical trials of a Chinese vaccine for Covid-19.

Florida State-Clemson game postponed amid coronavirus concerns
Swinney said if Florida State wants to play Clemson, it will have to travel to Death Valley or pay travel for the Tigers' travel. The first-year coach tested positive for the virus in September, missing the Seminoles' game with Miami.

Oxford University has set a target of 53 infections to start the interim analysis of its late-stage trial results, though "lots of cases" in its trial arms in Britain, South Africa and Brazil mean the exact number of infections reported could differ.

Older adults have an increased risk of COVID-19, so it's crucial that vaccines against the disease are effective in this age group.

The report said, "local and systemic reactions were more common in participants given ChAdOx1 nCoV-19 than in those given the control vaccine, and similar in nature to those previously reported (injection-site pain, feeling feverish, muscle ache, headache), but were less common in older adults (aged 56 years and above) than younger adults".

Volunteers got two doses of the vaccine or a placebo, and no serious side effects related to the AZD1222 vaccine were reported, the researchers said.

So far, the Brazilian federal government's main bet is on a vaccine being developed by AstraZeneca PLC, with which it has already signed a supply contract.